Research study Program year 2025 Source: CMS Open Payments

A Randomized, Multicentre, Open-Label, Phase 3 Study to Compare Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator Choice of Chemoimmunotherapy in Subjects with Previously Untreated CLL Without del(17p) or TP53 Mutation

Research payments

$8,010,610

238 payments

Through program year 2025, $8,010,610 in research payments was reported against A Randomized, Multicentre, Open-Label, Phase 3 Study to Compare Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator Choice of Chemoimmunotherapy in Subjects with Previously Untreated CLL Without del(17p) or TP53 Mutation, across 238 payments.

Paid by (largest first): Acerta Pharma LLC; AstraZeneca Pharmaceuticals LP
ClinicalTrials.gov: No trial number was reported for this study

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$285,247	20
2024	Research	$686,446	42
2023	Research	$1,357,900	28
2022	Research	$995,747	30
2021	Research	$2,626,880	46
2020	Research	$1,892,326	50
2019	Research	$166,065	22

Breakdown

Who paid Research payments · program years 2019–2025

Acerta Pharma LLC $8,003,713 236 payments
AstraZeneca Pharmaceuticals LP $6,898 2 payments

Who received the money Research payments · program years 2019–2025

Presbyterian Hospital Huntersville Teaching hospital · NC $1,656,605 13 payments
Translational Oncology Research International Organisation paid for research $1,241,981 26 payments
Dana Farber Cancer Institute, INC Organisation paid for research $628,807 7 payments
Dana-Farber Cancer Institute Teaching hospital · MA $626,946 11 payments
Norton Hospitals Inc Teaching hospital · KY $457,321 2 payments
Gabrail Cancer Research LLC Organisation paid for research $447,656 15 payments
Allegheny-Singer Research Institute Organisation paid for research $279,376 6 payments
University Of Pittsburgh Medical Center Hillman Cancer Center Organisation paid for research $257,518 4 payments
University of Maryland Baltimore Organisation paid for research $253,231 9 payments
University Of Pittsburgh Cancer Institute Organisation paid for research $242,759 6 payments

Usually the institution or organisation running the study, not a person.

Records

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

9 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.

Cite this record

“A Randomized, Multicentre, Open-Label, Phase 3 Study to Compare Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator Choice of Chemoimmunotherapy in Subjects with Previously Untreated CLL Without del(17p) or TP53 Mutation”, Who Paid My Doc, citing CMS Open Payments, program year 2025. https://www.whopaidmydoc.com/research-studies/a-randomized-multicentre-open-label-phase-3-study-to-compare-efficacy-and-safety-of-acalabrutinib-in-combination-with-venetoclax-with-and-without-obinutuzumab-compared-to-investigator-choice-of-chemoimmunotherapy-in-subjects-with-previously-untreated-cll-without-del-17p-or-tp53-mutation-59204098

Figures here may be reproduced with attribution and a link — see for journalists and researchers.